Blood pressure levels and mortality risk among hemodialysis patients in the dialysis outcomes and practice patterns study

Kidney International

Volumn 82, Issue 5, 2012, Pages 570-580

  Robinson, Bruce M ^a,b   Tong, Lin ^a   Zhang, Jinyao ^a   Wolfe, Robert A ^a   Goodkin, David A ^a   Greenwood, Roger N ^c   Kerr, Peter G ^d   Morgenstern, Hal ^a,e   Li, Yun ^a,f   Pisoni, Ronald L ^a   Saran, Rajiv ^f   Tentori, Francesca ^a   Akizawa, Tadao ^g   Fukuhara, Shunichi ^h   Port, Friedrich K ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c LISTER HOSPITAL   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g SHOWA UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

blood pressure; cardiovascular; hemodialysis; hypertension; mortality

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

EID: 84865237502     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.136     Document Type: Article

References (54)

1. Ezzati M, Lopez AD, Rodgers A et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360. (Pubitemid 35341298)
2. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223. (Pubitemid 40138015)
3. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
4. US Renal Data System: USRDS 2009. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In National Institutes of Health, National Institute of Diabetes and Digestive Disease and Kidney Diseases: Bethesda, MD, 2009.
5. Ansell D, Feehally J, Feest TG et al. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-S153.
6. UK Renal Registry Report 2007. In: UK Renal Registry of the Renal Association 2007.
7. Agarwal R, Nissenson AR, Batlle D et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297. (Pubitemid 37088191)
8. Port FK, Hulbert-Shearon TE, Wolfe RA et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517.
9. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817. (Pubitemid 40418386)
10. Li Z, Lacson Jr E, Lowrie EG et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606-615. (Pubitemid 44425376)
11. Zager PG, Nikolic J, Brown RH et al. U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54: 561-569.
12. Lowrie E, Huang WH, Lew NL et al. The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA (ed). Death on Hemodialysis. Kluwer Academic: Boston, 1994 pp 121-141.
13. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)
14. Greenland S, Lash TL. In: Rothman KJ, Greenland S, Lash TL (eds). Analysis of uncontrolled confounding. Modern Epidemiology. vol. 3rd edn Lippincott, Williams & Wilkins: Philadelphia, 2008, pp 365-370.
15. Johnston SC, Henneman T, McCulloch CE et al. Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol 2002; 156: 753-760. (Pubitemid 35155182)
16. Johnston SC. Combining ecological and individual variables to reduce confounding by indication: case study-subarachnoid hemorrhage treatment. J Clin Epidemiol 2000; 53: 1236-1241.
17. Morgenstern H. Ecologic studies. In: Rothman KJ, Greenland S, Lash TL (eds). Modern Epidemiology. 3rd edn. Lippincott, Williams & Wilkins: Philadelphia, 2008 pp 511-531.
18. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444-455. (Pubitemid 126412813)
19. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998; 19: 17-34. (Pubitemid 28279922)
20. Johnston J, DiNardo J. Econometric Methods. 4th edn McGraw-Hill: New York, 1997 xviii, 531 p.pp.
21. Brookhart MA, Rassen JA, Wang PS et al. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care 2007; 45: S116-S122.
22. Martens EP, Pestman WR, de Boer A et al. Instrumental variables: application and limitations. Epidemiology 2006; 17: 260-267.
23. Judge GG, Hill RC, Griffiths WE et al. Introduction to the Theory and Practice of Econometrics. 2nd edn John Wiley & Sons, New York, 1982.
24. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
25. Ramirez SP, Albert JM, Blayney MJ et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20: 1094-1101.
26. Brookhart MA, Wang PS, Solomon DH et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275.
27. Stukel TA, Fisher ES, Wennberg DE et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297: 278-285. (Pubitemid 46143305)
28. Bradbury BD, Do TP, Winkelmayer WC et al. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf 2009; 18: 932-940.
29. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864.
30. Stidley CA, Hunt WC, Tentori F et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17: 513-520.
31. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: 860-866.
32. Wizemann V, Wabel P, Chamney P et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574-1579.
33. Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385. (Pubitemid 26166411)
34. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
35. McIntyre CW, Burton JO, Selby NM et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008; 3: 19-26.
36. Dasselaar JJ, Slart RH, Knip M et al. Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant 2009; 24: 604-610.
37. McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int 2009; 76: 371-375.
38. Burton JO, Jefferies HJ, Selby NM et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914-920.
39. Shoji T, Tsubakihara Y, Fujii M et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220. (Pubitemid 39121031)
40. Agarwal R, Light RP. Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoring. Am J Kidney Dis 2009; 54: 693-701.
41. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
42. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
43. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4(Suppl 1): S79-S91.
44. Agarwal R, Alborzi P, Satyan S et al. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507.
45. Agarwal R, Peixoto AJ, Santos SF et al. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2006; 1: 389-398.
46. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147-2154.
47. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2: 1228-1234.
48. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2010; 77: 273-284.
49. Young E, Goodkin D, Mapes D et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57: S74-S81.
50. Pisoni RL, Gillespie BW, Dickinson DM et al. The dialysis outcomes and practice patterns study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7-15.
51. Wooldridge JM. Introductory Econometrics, Chapter 15. 4th edn 2002.
52. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 722-729. (Pubitemid 30612241)
53. Pisoni RL, Arrington CJ, Albert JM et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 2009; 53: 475-491.
54. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573-577 (Pubitemid 351664504)